AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04814173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-jaw mechanic total maxillary arch distalization
Description: A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
Study NCT04814173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: en-mass retraction
Description: A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
Study NCT04915365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
Study NCT04915365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
Study NCT05693428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
Study NCT05693428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoflurane
Description: isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
Study NCT05693428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
Study NCT06296784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-health psychoeducation
Description: e-health psychoeducation intervention provides information about BD clinical condition and symptoms, as well as identifying effective coping strategies to manage symptoms and the dysregulation of biological rhythms. The content covered the impact of the pandemic and its related restrictions on mental health, particularly on anxiety and depressive symptoms. The intervention comprised one session per week for two months, and each session lasted approximately an hour and a half. It was conducted by healthcare professionals.
Study NCT06012214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROBOTIC-ASSISTED ESOPHAGECTOMY
Description: Comparison between robotic and conventional minimally invasive esophagectomy
Study NCT06012214 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ROBOTIC-ASSISTED ESOPHAGECTOMY
Description: Comparison between robotic and conventional minimally invasive esophagectomy
Study NCT00614640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir patch
Description: DNA Vaccine
Study NCT00614640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: 10% dextrose (D-glucose) solution
Study NCT04665986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
Study NCT04665986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 90mg/m2 on day 1, every 3 weeks
Study NCT05513833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard School Screening and Referral
Description: Counties in the control condition will use standard hearing screening and standard referral by school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
Study NCT05513833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced mHealth Screening
Description: The enhanced screening protocol will consist of an mHealth-based hearing screen combined with tympanometry.
Study NCT05513833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specialty Telemedicine Referral
Description: The specialty telemedicine referral will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the specialty telemedicine referral and send details asynchronously to an audiologist for consultation.
Study NCT04888832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Work requirement exemption months
Description: Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
Study NCT06498843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: administration of an isotonic seawater solution (9g/L) in the nose
Description: 1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis, and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days
Study NCT06498843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: administration of a hypertonic seawater solution (21g/L) in the nose
Description: 1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days
Study NCT06357611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated technique
Description: The participant was in a supine position, with her upper limbs at her sides and her neck in a neutral position.~The researcher sat in a cephalic position, making contact with the participant's shoulders, without any movement, until 5 minutes had elapsed.
Study NCT06357611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~The researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. He then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively until the motor barrier was reached, and instructed her to perform an isometric contraction of the hamstrings. She was asked to perform three 7-second contractions with a 2 to 3-second interval, using approximately 20% of her maximum strength, gaining a new motor barrier between each set, for a total of three sets.
Study NCT06357611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4th ventricle technique and muscular energy technique
Description: The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~For CV-4, the researcher contacted the squamous portion of the occiput laterally, bringing it close to the posterior convexity of the occiput, bringing the skull into extension, changing the compression movement with decompression, until 3 minutes had elapsed.~For the MET, the researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. She then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively to the motor barrier, having been instructed to perform an isometric contraction of the hamstring. A total of 3 7-second contractions with a 2-3 second interval were requested, using approximately 20% of her maximum strength, and with a new motor barrier being gained between each series, for a total of 3 series.
Study NCT05454124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training visual sensitivity
Description: Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
Study NCT05454124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination training
Description: Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
Study NCT05931614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unlimited fluid restrictions
Description: Patients are recommended unlimited fluid intake
Study NCT04795752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare System
Description: TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
Study NCT04795752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
Study NCT05707104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds
Study NCT05707104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometrics exercises
Description: 1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6
Study NCT04603339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme delivered via telehealth
Description: 12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions
Study NCT06241144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Information and communication technology -based health behavior change support system
Description: Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
Study NCT05071742 — intervention group
Intervention type: GENETIC
Intervention: 2ml peripheral venous blood was collected to detect genetic genes
Description: Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection
Study NCT06204003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis/Hemp Isolate Extract
Description: Formulation: CBD (99%; 0.1% THC isolate)
Study NCT05482776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity functional training
Description: HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance.
Study NCT05482776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classic training group
Description: This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
Study NCT04974853 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cardio-complement
Description: Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
Study NCT05961124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
Study NCT03595072 — intervention group
Intervention type: OTHER
Intervention: observation of VNS stimulation effects
Description: ECOGs will be recorded during VNS stimulation and inter stimulation periods
Study NCT04920331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 140mg single intravenous administration (60 minutes)
Study NCT05136326 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiation
Description: External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
Study NCT05136326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
Study NCT05136326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/sqm p.o. 5 days/week for 5 weeks
Study NCT05270408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation (STARStim 8)
Description: Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
Study NCT05270408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation (STARStim 8)
Description: Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
Study NCT05270408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation (STARStim 8)
Description: Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
Study NCT04973566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.
Study NCT04973566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be administered subcutaneously.
Study NCT04973566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: HCQ will be administered orally.
Study NCT05233462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized dose
Description: intrathecal anesthesia with 10 mg of bupivacaine
Study NCT05233462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adjusted dose
Description: intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
Study NCT06061588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The use of virtual reality as an adjunct to routine treatment.
Study NCT04771559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 antibody test
Description: 5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples
Study NCT04218539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 10mg Psilocybin
Study NCT04218539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 25mg Diphenhydramine
Study NCT05463250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartwatch
Description: Wearing a smartwatch and having access to its data
Study NCT05901506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a Nurse-led, Motivational Interview
Description: Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
Study NCT05585203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total.
Study NCT05585203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
Study NCT05585203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
Study NCT06142474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
Study NCT05273411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester
Description: Single-dose pharmacokinetic study over 4 hours.
Study NCT05273411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-hydroxybutyric acid
Description: Beta-hydroxybutyric acid
Study NCT05273411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1,3-Butanediol
Description: 1,3-Butanediol